Dermatology
Latest News
Hydroquinone, found in skin-lightening agents worldwide, linked with increased skin cancer risk
“The magnitude of the risk was surprising,” one of the study authors said.
Latest News
VTE risk not elevated in AD patients on JAK inhibitors: Study
The labels of JAK inhibitors include a boxed warning describing an increased risk of “serious heart-related events such as heart attack or stroke...
From the Journals
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Patients with immune-mediated inflammatory diseases have weaker vaccine-induced immunity to COVID but are able to build a humoral immune response...
Latest News
Body contouring tops list of cosmetic procedures with adverse event reports
Cosmetic in-office treatments continue to gain popularity, but patients and providers may be underinformed of risks.
Latest News
Asian patients with psoriasis have shortest visits, study shows
The reasons for the difference are unclear and in need of further research, according to the study authors.
Latest News
Second opinions on melanocytic lesions swayed when first opinion is known
Downward and upward shifts in severity from an accurate diagnosis are concerning because of the likelihood they will lead to overtreatment or...
From the Journals
Abrocitinib evaluated in patients with and without prior dupilumab treatment
“These results ... support the use of abrocitinib in patients who might have received biologic therapy prior.”
Latest News
Consider essential oil allergy in patient with dermatitis
Allergic contact dermatitis to cannabis is probably “a lot less rare than we realize,” according to Dr. Brandon L. Adler.
Latest News
Why it’s important for dermatologists to learn about JAK inhibitors
“We are going to be getting a lot more indications for these drugs,” Dr. Andrew Blauvelt said.
Opinion
A White female presented with pruritic, reticulated, erythematous plaques on the abdomen
A White female with a medical history of arthritis, asthma, and iron deficient anemia presented with pruritic, reticulated, erythematous plaques...
News from the FDA/CDC
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.